Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

Fig. 1

Individual comparison of lymphomas shown on 18F-FDG and 68Ga-Pentixafor PET/CT. 68Ga-Pentixafor PET showed obviously higher intensity than 18F-FDG uptake in lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL). 68Ga-Pentixafor PET also detected more disease involvement in bone marrow, lymph nodes, and paramedullary disease in LPL. 68Ga-Pentixafor PET showed increased accumulation of radioactivity in follicular lymphoma (FL) and mantle cell lymphoma (MCL), but was lower than the 18F-FDG uptake. 68Ga-Pentixafor and 18F-FDG PET detected disease involvement with comparable uptake of both tracers in unclassified indolent B cell lymphoma (iBCL) and enteropathy associated T cell lymphoma (EATL). NK/T cell lymphoma (NKTCL) was very 18F-FDG-avid but was negative of 68Ga-Pentixafor uptake

Back to article page